<DOC>
	<DOCNO>NCT02093065</DOCNO>
	<brief_summary>Abnormalities gene encode Factor VIII ( FVIII ) result hemophilia A , X-linked recessive bleeding disorder prevalence 1 5000 male . Hemophilia A patient classify 3 different category base residual FVIII activity compare normal : mild ( 6-40 % ) , moderate ( 1-5 % ) severe ( &lt; 1 % ) . This categorization correlate degree bleed phenotype , completely define . Some patient hemophilia A bleed less often others despite identical plasma FVIII level . The cause ( ) phenotype heterogeneity hemophilia A remain largely unknown , despite number study possible factor . Activated platelet , addition role primary hemostasis , play major role secondary hemostasis ( coagulation ) provide phospholipid surface coagulation factor bind . A role platelets hemorrhagic propensity hemophilia A suggest past , small number study perform limitation assay perform number patient . The purpose present study determine whether platelet reactivity severe hemophilia A patient associate past bleeding frequency and/or predict future bleed frequency .</brief_summary>
	<brief_title>Platelet Function Patients With Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Patients severe hemophilia A prophylactically treat FVIII . Age least 2 year . Bleeding history least 6 month . IRBapproved inform consent . Presence FVIII inhibitor . Greater 7 day since active bleeding .</criteria>
	<gender>Male</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>severe hemophilia A</keyword>
	<keyword>coat platelet</keyword>
	<keyword>bleeding</keyword>
</DOC>